Zydus Lifesciences has received final approval from the United States Food and Drug Administration (US FDA) for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg.

Olmesartan Medoxomil and Hydrochlorothiazide, as the name suggests is a combination of two medicines: Olmesartan and Hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (sometimes called an ARB blocker) while hydrochlorothiazide is a diuretic (water pill). This combination of medicine is used to treat high blood pressure (hypertension). Lowering blood pressure may lower the risk of a stroke or heart attack. 

The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ.

In another development, the company has received approval for Apixaban Tablets, 2.5 mg and 5 mg. Apixaban blocks the activity of certain clotting substances in the blood. It is used to lower the risk of stroke or a blood clot in people with a heart rhythm disorder called atrial fibrillation. It is also used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery. It is also used for the treatment of blood clots in the veins of the legs or lungs and reduces the risk of them occurring again. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad.